GeneReach Biotechnology Asset Resilience Ratio

Latest as of June 2026: 28.49%

GeneReach Biotechnology asset resilience ratio. GeneReach Biotechnology (4171) has an Asset Resilience Ratio of 28.49% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 4171 days of operational coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

NT$244.49 Million

≈ $7.70 Million USD Cash + Short-term Investments

Total Assets

NT$858.12 Million

≈ $27.04 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio of GeneReach Biotechnology (2018–2025)

Asset resilience ratio of GeneReach Biotechnology from 2018 to 2025. This chart shows how GeneReach Biotechnology's Asset Resilience Ratio has changed over time. Read how much debt does GeneReach Biotechnology carry for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down GeneReach Biotechnology's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see GeneReach Biotechnology (4171) total assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$244.49 Million	28.49%
Total Liquid Assets	NT$244.49 Million	28.49%

Asset Resilience Insights

Very High Liquidity: GeneReach Biotechnology maintains exceptional liquid asset reserves at 28.49% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

GeneReach Biotechnology Industry Peers by Asset Resilience Ratio

Compare GeneReach Biotechnology's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Bavarian Nordic CO:BAVA	Biotechnology	10.83%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

GeneReach Biotechnology Asset Resilience Ratio by Year (2018–2025)

GeneReach Biotechnology asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for GeneReach Biotechnology.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	28.34%	NT$249.69 Million ≈ $7.87 Million	NT$881.05 Million ≈ $27.76 Million	-8.56pp
2024-12-31	36.90%	NT$393.49 Million ≈ $12.40 Million	NT$1.07 Billion ≈ $33.60 Million	+10.11pp
2023-12-31	26.79%	NT$315.10 Million ≈ $9.93 Million	NT$1.18 Billion ≈ $37.05 Million	+25.84pp
2022-12-31	0.95%	NT$15.36 Million ≈ $483.77K	NT$1.62 Billion ≈ $51.10 Million	+0.13pp
2021-12-31	0.82%	NT$13.84 Million ≈ $436.04K	NT$1.68 Billion ≈ $53.07 Million	-2.62pp
2020-12-31	3.44%	NT$42.72 Million ≈ $1.35 Million	NT$1.24 Billion ≈ $39.08 Million	-30.26pp
2018-12-31	33.70%	NT$233.82 Million ≈ $7.37 Million	NT$693.83 Million ≈ $21.86 Million	--

pp = percentage points

About GeneReach Biotechnology

TWO:4171 Taiwan Biotechnology

Market Cap

$28.84 Million

NT$915.41 Million TWD

Market Cap Rank

#23735 Global

#1490 in Taiwan

Share Price

NT$16.10

Change (1 day)

-0.31%

52-Week Range

NT$16.10 - NT$22.85

All Time High

NT$246.40